Abstract: A cartridge for a valve housing having outlets, the cartridge comprising a stationary body sleeve for fixed insertion within the housing and having outlet ports permanently aligned with the outlets of the housing, a moveable substantially hollow stem sleeve inserted within the stationary body sleeve and having an opening selectively alignable with the ports of the stationary body sleeve, the body sleeve and hollow stem being connected to one another by a retaining ring which aligns and maintains the cartridge as a unit in the housing.

Abstract: A process for making Fluconazole is provided comprising carrying out the following scheme of reaction: ##STR1##

Abstract: A combination for administration to a mammal which combination employs a therapeutically effective amount of a medicinal and/or therapeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.

Abstract: The use of:(a) a non-steroidal anti-inflammatory agent,and(b) hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and subunits of hyaluronic acid,in the manufacture of a pharmaceutical composition for inhibiting, controlling and/or regressing angiogenesis in a therapy wherein dosage amounts taken from the composition each comprise:(1) a therapeutically effective amount of component (a); and(2) a therapeutically effective amount of the hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and sub-units of hyaluronic acid, the pharmaceutical composition being characterized in that for each dosage amount taken from the pharmaceutical composition, the amount of components (a) and (b) inhibit, control and/or regress angiogenesis.

Abstract: A key-retaining system is provided which includes a key holder and a key holder retainer. The key holder is a substantially continuous member having ends and sides, for example one continuous wire, and provides an interior space between the sides and ends of the member. The ends are separated by a predetermined distance substantially greater than the length of a key. One of the sides or ends includes a device to permit fastening of keys upon the member. The key holder retainer includes a hollow extending substantially from end to end of the key holder retainer and adapted to receive the key holder in use. Keys may be fastened on the key holder and positioned in a flat position within the interior space of the key holder. The key holder retainer is then friction fit onto the key holder remote the key heads.

Abstract: The invention is directed toward a parking assist device which is removably affixed in relation to a surface and is adapted to engage the on coming wheels of a vehicle and provide upon being engaged by the wheels of a vehicle a signal to the operator to stop the vehicle. The signal may be produced by a mechanical, electrical or other means.

Abstract: A method is provided of preventing arterial restenosis of an animal after the arteries have been traumatized. The method comprises the administration of a therapeutically effective non-toxic amount of hyaluronic acid and/or pharmaceutically acceptable salts thereof to the animal to prevent narrowing of the arteries. The form of hyaluronic acid is selected from hyaluronic acid and pharmaceutically acceptable salts thereof having a molecular weight less than 750,000 daltons.

Abstract: A combination for administration to a mammal which combination employs a therapeutically effective amount of a medicinal and/or therapeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.

Abstract: A method of treating anorectal disease is provided which comprises applying to anorectal tissue in need of such treatment an effective amount of a composition comprising a pharmaceutically acceptable carrier and hyaluronic acid or a pharmaceutically acceptable salt thereof in an amount8 of up to about 10% by weight.

Abstract: A method of treating pain topically, said method comprising administering topically to the skin or exposed tissue of a human, a dosage amount of a pharmaceutical composition, said dosage amount comprising (1) a non-steroidal anti-inflammatory drug (NSAID) in a therapeutically effective amount to treat pain of the skin or exposed tissue and (2) a form of hyaluronic acid selected from the group consisting of hyaluronic acid, its non-toxic salts and combination thereof being between 1% and 3% by weight of the composition, characterized in that said dosage amount of said composition is in a dosage form suitable for topical application to the skin or exposed tissue and in a dosage amount in which component (2) exceeds 10 mg/cm.sup.

Abstract: A method of treating a disease or condition in a human treatable by a medicine and/or therapeutic agent which may be transported by an agent to the site in need of treatment in the body and which agent may also transport the medicine and/or therapeutic agent to the liver (by for example, the transport agent binding to receptors on the liver) is provided comprising:(a) administering an effective non-toxic amount of a first agent which does not bind to receptors at the site in need of treatment but which binds with receptors of the liver thereby "down regulating" the liver; and,(b) thereafter administering an effective non-toxic amount of a medicine and/or therapeutic agent and an effective amount of a second agent which is a transport agent and is a different agent from the first agent which binds to the site in need of treatment and would be capable of binding to the sites of the liver if the liver had not been "down regulated" so that its binding capacity for the second agent has been substantially reduced b

Abstract: A method of clearing atherosclerosis comprising the step of administering to a patient, at least one dosage amount of a pharmaceutical composition comprising an effective non-toxic amount of each of a chelating agent, a non-steroidal anti-inflammatory drug (NSAID), an anti-oxidant and a form of hyaluronic acid, selected from hyaluronic acid, salts thereof, homologues, analogues, derivatives, esters, complexes, fragments and subunits.

Abstract: A method of administering a medicinal agent and an effective amount of a form of hyaluronic acid for decreasing side effects associated with using the agent alone in treating a disease or condition in mammals is disclosed. The agent may be a non-steroidal anti-inflammatory drug (NSAID). The amount of hyaluronic acid is sufficient enough to provide a dosage greater than 200 mg/70 kg person. The molecular weight of the form of hyaluronic acid may be less than 750,000 daltons.

Abstract: A topically administrable pharmaceutical composition is disclosed which comprises a therapeutically effective amount of a drug which inhibits prostaglandin synthesis, and an amount of a form of hyaluronic acid sufficient to transport the composition through the skin into the epidermis or dermis where the composition remains until discharged via the lymphatic system, wherein(a) the drug is 1-5% by weight of the composition, and(b) the form of hyaluronic acid is 1-3% by weight of the composition, has a molecular weight greater than about 150,000 daltons and less than 750,000 daltons, and is selected from the group consisting of hyaluronic acid and salts thereof.

Abstract: An inflatable portable substantially collapsible structure comprising an inflatable substantially collapsible playing field having at least two walls, a top and a bottom, at least one object director to direct an object with a fluid along or above the playing surface and at least one score area.

Abstract: A method of treating a human having a disease or condition characterized by macrophage, neutrophile or other white blood cell infiltration into the area damaged by the disease or condition, the method comprising administering to the human an effective amount of hyaluronic acid and/or salts thereof for a period of time until the administration is no longer required.

Abstract: A preparation which is compatible with the skin for the treatment of labial disease and acne. The preparation comprises a mixture of:(a) at least one compound selected from an antiseptic compound and an anesthetic compound which is:(i) a terpene,(ii) a phenolic compound, or(iii) an alcohol;(b) a quaternary ammonium antiseptic compound;(c) an antiseptic compound selected from compounds containing iodine, salts thereof and complexes thereof dissolved in an organic skin penetrating solvent, wherein said solvent comprises acetone.

Abstract: A process of manufacture of:R--CH.sub.2 --S--CH.sub.2 --CH.sub.2 --NH.sub.2 2HC1wherein R is selected from the group consisting of ##STR1## is provided, the said process comprising reacting R--CH.sub.2 OH.HCL with HSCH.sub.2 CH.sub.2 NH.sub.2 .HC1 in a suitable solvent in the presence of an effective amount of Hydrochloric acid.

Abstract: A process for making Fluconazole is provided comprising carrying out the following scheme of reaction: ##STR1##

Abstract: A closure assembly is provided including a track and a slidable and pivotable closure member. The closure member is engaged with the track proximate first and second pivots adjacent the pivotable end of the member, the first and second pivots being interconnected by a multiple segment shaft (for example at least two portions) (for example telescoping) which provides for accurate installation, retention, removal, adjustment and alignment of the first and second pivots in a substantially parallel line for pivotally supporting the closure member so that it may be safely and securely pivoted away from the closure assembly. Improvements to the abovementioned structure are also provided.